These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19952950)

  • 1. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
    Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
    J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
    Capuron L; Ravaud A; Miller AH; Dantzer R
    Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
    Ziefle S; Egberts F; Heinze S; Volkenandt M; Schmid-Wendtner M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Heinz A; Hauschild A; Schaefer M
    J Immunother; 2011 May; 34(4):403-8. PubMed ID: 21499123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
    Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
    Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
    Beratis S; Katrivanou A; Georgiou S; Monastirli A; Pasmatzi E; Gourzis P; Tsambaos D
    J Psychosom Res; 2005 Jan; 58(1):15-8. PubMed ID: 15771865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation.
    Chapman J; Oser M; Hockemeyer J; Weitlauf J; Jones S; Cheung R
    Am J Gastroenterol; 2011 Dec; 106(12):2123-32. PubMed ID: 21826113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
    Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
    Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits.
    Berlin I; Covey LS
    Addiction; 2006 Dec; 101(12):1814-21. PubMed ID: 17156181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
    Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
    J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C.
    Amodio P; De Toni EN; Cavalletto L; Mapelli D; Bernardinello E; Del Piccolo F; Bergamelli C; Costanzo R; Bergamaschi F; Poma SZ; Chemello L; Gatta A; Perini G
    J Affect Disord; 2005 Jan; 84(1):93-8. PubMed ID: 15620390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring depressive symptoms among treatment-resistant seizure disorder patients: POMS Depression scale as an alternative to the BDI-II.
    Griffith NM; Szaflarski JP; Szaflarski M; Kent GP; Schefft BK; Howe SR; Privitera MD
    Epilepsy Behav; 2005 Sep; 7(2):266-72. PubMed ID: 16005686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Ann Pharmacother; 2004 Oct; 38(10):1655-9. PubMed ID: 15304625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Depression during interferon therapy in chronic hepatitis C patients--a prospective study].
    Otsubo T; Miyaoka H; Kamijima K; Onuki M; Ishii M; Mitamura K
    Seishin Shinkeigaku Zasshi; 1997; 99(3):101-27. PubMed ID: 9136611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
    Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
    Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Obesity, alexithymia, psychopathology and binge eating: a comparative study of 40 obese patients and 32 controls].
    De Chouly De Lenclave MB; Florequin C; Bailly D
    Encephale; 2001; 27(4):343-50. PubMed ID: 11686056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
    Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
    J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.